Enliven Therapeutics, Inc.

US$49.43As of Sun 8 Nov 2026, 12:00 UTC
NASDAQ:ELVNHealthcare
Country USA
PE (Fwd) •••
TSR 4Y CAGR 25.22%
Div yield —
ROE (16.77%)
Biotechnology
Beta (5Y) 0.36
PE TTM —
TSR TTM 111.06%
Mkt cap US$3.638B
ROIC (12.49%)
SE Grade™
Value
Quality
Moat
Consensus
Reference
$54
9.26%
(9.93%)
Hold 1|8|6|3|5
4Q25
1Q26
2Q26
3Q26
Earnings per share$
0.73
0.74
0.82
0.80
10.56%
12.35%
12.64%
12.04%
Revenue$M
342.0
359.8
375.4
381.9
6.84%
14.48%
18.10%
15.48%
Peers (US$3.638B)
Cap (US$)
PE
Capital
TTM
5Y
10Y
Leveragex
0.860
0.120
0.119
EBIT/Intx
17.04
0.127
0.143
Own earn%
(105.32)
39.76
37.34
Sh yield%
21.71
34.04
33.90
Owners
Insiders/Inst%
13.52
32.74
Short interest%
4.08
SBC / revenue%
3.45
Record
10Y
Profitable years
10/10
Revenue growth years
10/10
EPS growth years
10/10
Dividend streakyrs
17
Op margin range%
11–16
$1 testx
—
Incr. ROIC%
−6